Ocular Involvement of Behçet's Syndrome: a Comprehensive Review (Q38211813)

31 August 2017

Ocular Involvement of Behçet's Syndrome: a Comprehensive Review (English)

1 reference

31 August 2017

0 references

Yilmaz Ozyazgan

1

1 reference

31 August 2017

Didar Ucar

series ordinal

2

1 reference

31 August 2017

Gulen Hatemi

series ordinal

3

1 reference

31 August 2017

Yusuf Yazici

series ordinal

4

1 reference

31 August 2017

15 May 2014

1 reference

Clinical Reviews in Allergy & Immunology

31 August 2017

1 reference

31 August 2017

49

1 reference

31 August 2017

3

1 reference

31 August 2017

298-306

1 reference

https://scigraph.springernature.com/pub.10.1007/s12016-014-8425-z

31 August 2017

0 references

cites work

Differential diagnosis of behçet uveitis

1 reference

https://api.crossref.org/works/10.1007%2FS12016-014-8425-Z

Clinical features of chinese patients with Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-014-8425-Z

Behçet's syndrome: disease manifestations, management, and advances in treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-014-8425-Z

Demographic and clinical features of uveitis in tertiary centers in Turkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-014-8425-Z

Influence of age of onset and patient's sex on the prevalence and severity of manifestations of Behçet's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-014-8425-Z

The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-014-8425-Z

Uveitis in Behçet disease: an analysis of 880 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-014-8425-Z

Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-014-8425-Z

Vasculitis in Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-014-8425-Z

A controlled trial of azathioprine in Behçet's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-014-8425-Z

Azathioprine in Behcet's syndrome: effects on long-term prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-014-8425-Z

Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet's syndrome: a single masked trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-014-8425-Z

Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-014-8425-Z

Treatment of ocular symptoms of Behçet's disease with interferon alpha 2a: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-014-8425-Z

Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-014-8425-Z

Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-014-8425-Z

Effect of infliximab on sight-threatening panuveitis in Behçet's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-014-8425-Z

Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-014-8425-Z

Therapeutic use of infliximab in sight threatening uveitis: retrospective analysis of efficacy, safety, and limiting factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-014-8425-Z

Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-014-8425-Z

A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet's disease: a comparative 4-week study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-014-8425-Z

Multicenter study of infliximab for refractory uveoretinitis in Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-014-8425-Z

Regression of optic disc neovascularization in patients with Behçet's uveoretinitis after infliximab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-014-8425-Z

Adalimumab for sight-threatening uveitis in Behçet's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-014-8425-Z

Clinical experience with adalimumab in the treatment of ocular Behçet disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-014-8425-Z

Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet's disease on infliximab therapy

21 January 2018

1 reference

12 December 2020

Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study

1 reference

12 December 2020

Canakinumab in a patient with juvenile Behcet's syndrome with refractory eye disease

1 reference

12 December 2020

The eighth Frederick H. Verhoeff Lecture. presented by saiichi mishima, MD Behçet's disease in Japan: ophthalmologic aspects

1 reference

12 December 2020

Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behçet uveitis

1 reference

12 December 2020

Interferon-alpha 2b for refractory ocular Behçet's disease

1 reference

12 December 2020

Comparison of presenting features and three-year disease course in Turkish patients with Behçet uveitis who presented in the early 1990s and the early 2000s

1 reference

12 December 2020

Intravitreal infliximab for sight-threatening relapsing uveitis in Behçet disease: a pilot study in 15 patients

1 reference

12 December 2020

Evaluation of conventional therapy versus cyclosporine A in Behçet's syndrome

1 reference

12 December 2020

Validity and agreement of uveitis experts in interpretation of ocular photographs for diagnosis of Behçet uveitis.

1 reference

12 December 2020

Ocular vasculitis in Behçet's disease. A pathological and immunohistochemical study

1 reference

12 December 2020

Results of interferon-alfa therapy in patients with Behçet uveitis

1 reference

12 December 2020

Interferon-a (IFN-a) application versus tumor necrosis factor-a antagonism for ocular Behçet's disease: focusing more on IFN

1 reference

12 December 2020

Anakinra for resistant Behçet uveitis: why not?

1 reference

12 December 2020

The rate of visual loss in Behçet's disease

1 reference

12 December 2020

Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis

1 reference

12 December 2020

10.1007/S12016-014-8425-Z

Identifiers

DOI

1 reference

Dimensions Publication ID

31 August 2017

0 references

1 reference